Show simple item record

dc.creatorGutiérrez, José María
dc.creatorLomonte, Bruno
dc.creatorLeón Montero, Guillermo
dc.creatorRucavado Romero, Alexandra
dc.creatorChaves Mora, Fernando
dc.creatorAngulo Ugalde, Yamileth
dc.date.accessioned2016-12-01T14:20:06Z
dc.date.available2016-12-01T14:20:06Z
dc.date.issued2007
dc.identifier.citationhttp://www.eurekaselect.com/59930/articlees_ES
dc.identifier.issn1873-4286
dc.identifier.urihttps://hdl.handle.net/10669/29338
dc.description.abstractThe therapy of snakebite envenomation has been based on the parenteral administration of animal-derived antivenoms. Despite the success of this treatment at reducing the impact of snakebite mortality and morbidity, mostly due to their capacity to neutralize systemically- acting toxins, antivenoms are of relatively low efficacy in the prevention of venom-induced local tissue damage, which often leads to permanent disability. The issue of safety also remains a concern, particularly for some antivenoms which induce a relatively high incidence of adverse reactions. Consequently, there is a need to improve the therapy of snakebite envenomations on the following lines: (a) the technologies to produce antivenoms require improvements aimed at obtaining more refined preparations of higher efficacy and safety, while being affordable for the public health systems of developing countries. (b) The growing knowledge on the biochemistry and toxicology of snake venoms should pave the way for the identification of natural and synthetic inhibitors of venom toxins, particularly of those involved in local tissue pathology. Such inhibitors might become a highly effective therapeutic tool for the abrogation of venominduced local tissue damage. (c) A better knowledge of the inflammatory events secondary to venom actions may open the possibility of modulating such response, in order to prevent further tissue damage and to promote successful tissue repair and regeneration. A global partnership, involving many participants and combining scientific, technological and public health actions, is required to achieve a leap forward in the treatment of snakebite envenomations world-wide.es_ES
dc.language.isoen_USes_ES
dc.sourceCurrent Pharmaceutical Design; Volumen 13, Número 28. 2007es_ES
dc.subjectAntivenomes_ES
dc.subjectMetalloproteinase Inhibitorses_ES
dc.subjectPhospholipase A2 Inhibitorses_ES
dc.subjectNecrosises_ES
dc.subjectHemorrhagees_ES
dc.subjectInflammationes_ES
dc.subjectSnake venomes_ES
dc.titleTrends in Snakebite Envenomation Therapy: Scientific, Technological and Public Health Considerationses_ES
dc.typeartículo científicoes_ES
dc.identifier.doi10.2174/138161207782023784
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP)es_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record